Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 13Other hematologic neoplasm 2Myeloid 2Lymphoid 2Genitourinary 1

Conditions

Prostatic Neoplasms 747Carcinoma, Renal Cell 237Urinary Bladder Neoplasms 212Carcinoma, Transitional Cell 115Breast Neoplasms 100Kidney Neoplasms 97Neoplasms 91Carcinoma, Non-Small-Cell Lung 86Melanoma 82Ovarian Neoplasms 81Colorectal Neoplasms 76Neoplasm Metastasis 69Non-Muscle Invasive Bladder Neoplasms 58Lung Neoplasms 58Pancreatic Neoplasms 49Endometrial Neoplasms 46Sarcoma 43Stomach Neoplasms 42Uterine Cervical Neoplasms 41Carcinoma, Hepatocellular 36Adenocarcinoma 35Wilms Tumor 33Esophageal Neoplasms 33Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 31Head and Neck Neoplasms 29Testicular Neoplasms 25Metastatic Castration-resistant Prostate Cancer 25Disease 24Colonic Neoplasms 24

Interventions

piperine 1Curcumin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Monoclonal Gammopathy of Undetermined Significance × Genitourinary × 90 days × Clear all
NCT04731844 2026-05-12

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

University of Rochester

Phase 2 Completed
30 enrolled 13 charts
GenitourinaryPlasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡